International REACH Forgiveness Intervention
1 other identifier
interventional
4,598
4 countries
5
Brief Summary
Six sites spanning five regions (Hong Kong, Colombia, Indonesia, Ukraine, South Africa) will administer a forgiveness workbook intervention in a randomized design with a stepped, waitlist intervention deployment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Feb 2020
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 4, 2020
CompletedFirst Posted
Study publicly available on registry
February 6, 2020
CompletedStudy Start
First participant enrolled
February 11, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 25, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 25, 2021
CompletedJanuary 5, 2024
January 1, 2024
1.7 years
February 4, 2020
January 4, 2024
Conditions
Outcome Measures
Primary Outcomes (3)
Depression (BSI)
Brief Symptom Index, minimum value = 0, maximum value = 4. Higher scores indicates a higher psychological distress.
4 months
Anxiety (BSI)
Brief Symptom Index. minimum value = 0, maximum value = 4. Higher scores indicates a higher psychological distress.
4 months
Forgiveness (TRIM)
Transgression-Related Interpersonal Motivations, minimum value = 1, maximum value = 5. The higher the score, the more unforgiving the person is.
4 months
Secondary Outcomes (4)
Trait Forgiveness (TSF)
4 months
Forbearance (FS)
4 months
Decision to Forgive (DTSF)
4 months
Flourishing
4 months
Study Arms (2)
Immediate Treatment
EXPERIMENTALParticipants in this group will receive treatment/intervention immediately.
Delayed Treatment
EXPERIMENTALParticipant in this group will receive treatment/intervention 2-week later.
Interventions
Participants will be asked to complete the REACH Forgiveness Workbook
Eligibility Criteria
You may qualify if:
- Must be able to read and comprehend the materials in the workbook
- Must be 18 years old or above
- Have someone in mind they want to forgive
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- City University of Hong Konglead
- Harvard Universitycollaborator
- Stanford Universitycollaborator
Study Sites (5)
Universidad del Sinú
Córdoba, Colombia
Universitas Gunadarma
Depok, Indonesia
The South African and Africa Chapter of the International Association of Assessing Officers
Pretoria, South Africa
Realis Center for Education and Research
Kyiv, Ukraine
Ukrainian Institute of Arts and Sciences
Kyiv, Ukraine
Related Publications (1)
Ho MY, Worthington EL, Cowden RG, Bechara AO, Chen ZJ, Gunatirin EY, Joynt S, Khalanskyi VV, Korzhov H, Kurniati NMT, Rodriguez N, Anastasiya Salnykova A, Shtanko L, Tymchenko S, Voytenko VL, Zulkaida A, Mathur MB, VanderWeele TJ. International REACH forgiveness intervention: a multisite randomised controlled trial. BMJ Public Health. 2024 Mar 13;2(1):e000072. doi: 10.1136/bmjph-2023-000072. eCollection 2024 Jun.
PMID: 40018096DERIVED
Study Officials
- PRINCIPAL INVESTIGATOR
Man Yee Ho, PhD
City University of Hong Kong
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
February 4, 2020
First Posted
February 6, 2020
Study Start
February 11, 2020
Primary Completion
October 25, 2021
Study Completion
October 25, 2021
Last Updated
January 5, 2024
Record last verified: 2024-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ANALYTIC CODE
- Time Frame
- After the embargo period (30 April, 2024)
Data, which will be used for meta-analysis, reproducibility, and replication purposes, will be disclosed after the embargo period (30 April, 2024).